Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Mainz BioMed N.V., corporate

Mainz BioMed N.V.,

15.11.2021 - 09:04:17

Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World's Largest Medical Trade Fair

DGAP-News: Mainz BioMed N.V.

/ Key word(s): Miscellaneous

Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World's Largest Medical Trade Fair

15.11.2021 / 09:01

The issuer is solely responsible for the content of this announcement.

BERKELEY, US - MAINZ, Germany - NOVEMBER 15, 2021 Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that Company representatives will be attending MEDICA 2021 to showcase ColoAlert, its highly efficacious and easy-to-use diagnostic test for colorectal cancer. MEDICA, the world's largest medical trade fair, takes place in D?sseldorf, Germany from November 15-18th, 2021. Throughout the conference, Mainz will be hosting meetings in Hall 3, Stand J27. "On the heels of our successful IPO on Nasdaq this past November, we are thrilled to participate in this important industry forum as we begin ramping-up commercial activities for ColoAlert, our flagship product, " commented Guido Baechler, Chief Executive Officer of Mainz Biomed. MEDICA 2021 is expected to attract almost 3000 exhibitors and visitors from over 50 countries working across all sectors of the healthcare industry. The 40 year old event brings together leading figures within healthcare, research, and politics to demonstrate and discuss the latest innovations in outpatient and clinical care and themes including laboratory technology and diagnostics, sports medicine & physiotherapy, big data, interventional imaging and surgery and telemedicine.About ColoAlertwww.mainzbiomed.comFor media enquiries, please contact press@mainzbiomed.com For investor enquiries, please contact ir@mainzbiomed.com Forward Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

15.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.dgap.de

Language: English Company: Mainz BioMed N.V. Robert-Koch-Strasse 50 55129 Mainz

Germany Internet: mainzbiomed.com EQS News ID: 1248873 ? End of News DGAP News Service


@ dgap.de